Core Insights - Alvotech has announced the acquisition of Ivers-Lee Group to expand its assembly and packaging capacity for biosimilar medicines, integrating Ivers-Lee into its Technical Operations division while maintaining its status as a separate legal entity [1][2][4] Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar market with a fully integrated approach and broad in-house capabilities [6] - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [6] Acquisition Details - Ivers-Lee, founded in 1947, specializes in high-quality assembly and packaging services for the pharmaceutical sector and operates in Burgdorf, Switzerland, and Lörrach, Germany [3][5] - The integration of Ivers-Lee is expected to provide Alvotech with added flexibility and capacity to meet the growing global demand for biosimilars, particularly with three new biosimilars set to launch in 2025 [2][5] Operational Capabilities - Ivers-Lee's operations include the assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials, with a GMP license and FDA approval for its Burgdorf site [5] - The company will continue to service its existing clients and provide contract manufacturing organization (CMO) services, including blister and stick-pack activities [5]

Core Viewpoint - Alvotech has announced the acquisition of Ivers-Lee Group to expand its assembly and packaging capacity, supporting its growth plans in the biosimilar market [1][2]. Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space with a fully integrated approach and broad in-house capabilities [6]. - The company has two approved biosimilars, Humira (adalimumab) and Stelara (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [6]. Acquisition Details - Ivers-Lee, a family-owned business established in 1947, specializes in high-quality assembly and packaging services for the pharmaceutical sector and will be integrated into Alvotech's Technical Operations division [3][5]. - The acquisition is expected to provide Alvotech with added flexibility and capacity to meet the increasing global demand for biosimilars, particularly as the company prepares to launch three new biosimilars in 2025 [2][4]. Operational Integration - Ivers-Lee's operations will continue to service its existing clients while also integrating capabilities such as the assembly and packaging of autoinjectors, pre-filled syringes, and safety devices [5]. - Peter Schüpbach, managing director of Ivers-Lee, will join Alvotech's Technical Operations senior leadership team post-acquisition, ensuring continuity in management [3]. Market Position - Alvotech has formed strategic commercial partnerships across various global markets, including the United States, Europe, Japan, and parts of South America, enhancing its market reach and local expertise [6].